The review found no eligible studies for this question.
Heparin showed no clear difference in PE (symptomatic, asymptomatic, non‐fatal) (timing not specified) compared with placebo (low certainty).
The review found no eligible studies for this question.
(Oral or intravenous) prostanoid showed no clear difference in ulcer healing compared with placebo (moderate certainty).
(Oral or intravenous) prostanoid showed no clear difference in complete relief of rest pain compared with placebo (moderate certainty).
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with placebo (moderate certainty).
Anticoagulant leads to lower recurrence of VTE ( compared with no intervention or placebo (high certainty).
Anticoagulant showed no clear difference in major bleeding ( compared with no intervention or placebo (low certainty).
Anticoagulant leads to lower recurrence of DVT ( compared with no intervention or placebo (high certainty).
Anticoagulant showed no clear difference in PE ( compared with no intervention or placebo (low certainty).
Anticoagulant leads to higher clinically relevant non‐major bleeding ( compared with no intervention or placebo (high certainty).
Anticoagulant showed no clear difference in overall mortality ( compared with no intervention or placebo (low certainty).
TNF‐α blockers intervention may leads to lower treatment resistance compared with placebo or additional treatment (low certainty).
TNF‐α blockers intervention showed no clear difference in incidence of coronary artery abnormalities compared with placebo or additional treatment (low certainty).
TNF‐α blockers intervention may leads to lower adverse effects after treatment initiation: infusion reactions compared with placebo or additional treatment (low certainty).
TNF‐α blockers intervention showed no clear difference in adverse effects after treatment initiation: infections compared with placebo or additional treatment (low certainty).
It is very uncertain whether TNF‐α blockers intervention changes adverse effects after treatment initiation: cutaneous reactions (rash) compared with placebo or additional treatment (very low certainty).